Eli Lilly & Co. (LLY) Presents Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Next Articles